RedHill Biopharma (RDHL) shares were up Tuesday after the company said it started a phase 2 clinical study of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer.
The 80-patient trial will test the potentially enhancing effect of opaganib in overcoming resistance to standard of care androgen receptor pathway inhibition treatment.
The study is financially backed by Bayer and the Ramsay Hospital Research Foundation, RedHill said.
Price: 6.18, Change: +0.43, Percent Change: +7.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.